Hunt Anthony has disclosed a significant transaction involving the sale of shares in BioLife Solutions, Inc. The filing, made on October 8, 2026, reveals that the transaction occurred on October 6, 2026, in connection with a merger between BioLife Solutions and Repligen Corporation. This merger is expected to reshape the competitive landscape in the electromedical sector.
Hunt Anthony, identified as a director of BioLife Solutions, reported the disposition of 15,046 shares of common stock. Following this transaction, Hunt Anthony no longer holds any shares in the company. The filing indicates that the shares were converted into cash and shares of Repligen common stock as part of the merger agreement.
Background
Hunt Anthony is associated with BioLife Solutions, Inc., which is classified under the electromedical and electrotherapeutic apparatus sector. The company has a history of filings, including several Form 4 submissions, with the most recent prior to this one dated June 12, 2026. The company is based in Bothell, Washington, and operates in the medical technology space.
What the Filing Says
The SEC filing details that Hunt Anthony disposed of shares as part of the merger agreement, stating: "Reflects the disposition of shares of common stock of BioLife Solutions, Inc. in connection with the consummation on October 6, 2026 of the merger..." This indicates that the transaction was a direct result of the merger with Repligen Corporation.
Impact
This transaction may affect stakeholders within BioLife Solutions, including investors and employees, as the merger with Repligen Corporation could lead to changes in company strategy and operations. The merger could also alter competitive dynamics in the electromedical industry, potentially impacting other companies in the sector.
What's Next
The filing does not say what happens next.